tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tolba RH et al. Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life. 2001 Nov-Dec Transplant. Proc. pmid:11750475
Ferraresso M et al. Conversion from cyclosporine to tacrolimus for refractory acute rejection in pediatric kidney transplant recipients: a single-center experience. 2001 Nov-Dec Transplant. Proc. pmid:11750525
Rostaing L et al. Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. 1998 Transplant. Proc. pmid:9636520
Morris-Stiff G et al. Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636521
Kanter J et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. 2009 Jul-Aug Transplant. Proc. pmid:19715860
Corry RJ et al. Pancreas transplantation without antibody therapy. 1998 Transplant. Proc. pmid:9532050
Rafael-Valdivia L et al. How long should initiation of calcineurin inhibitors be delayed to protect renal function in liver transplantation? 2011 Transplant. Proc. pmid:21486577
Lemmens HP et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. 1994 Transplant. Proc. pmid:7527983
Chakkera HA et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375287
Toda F et al. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119909
Tian Ch et al. B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375291
Propper DJ et al. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens. 1993 Transplant. Proc. pmid:7679837
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Jin MB et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. 1996 Transplant. Proc. pmid:8623243
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Žilinská Z et al. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. 2016 Transplant. Proc. pmid:27788794
Bekersky I et al. Bioequivalence of a new strength tacrolimus capsule under development. 1998 Transplant. Proc. pmid:9636591
Kobashigawa JA Postoperative management following heart transplantation. 1999 Transplant. Proc. pmid:10455966
Watanabe K et al. Synergistic effect of short-term fractionated lymphoid irradiation with initial high doses of FK506 on the induction of tolerance to kidney allografts in dogs. 1998 Transplant. Proc. pmid:9474940
Kaminska D et al. Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis. 2005 Transplant. Proc. pmid:15848526
Woodle ES et al. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. 1996 Transplant. Proc. pmid:8623495
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
Watanabe Y et al. The expression of nonmuscle myosin heavy chain in rat renal transplantation. 1999 Transplant. Proc. pmid:10578260
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Wang CH et al. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation. 2008 Transplant. Proc. pmid:18929812
Iwahori T et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. 2005 Transplant. Proc. pmid:15919450
Lee TK et al. Bacterial translocation and the role of postoperative selective bowel decontamination in small intestinal transplantation. 1994 Transplant. Proc. pmid:7518154
Takeuchi H et al. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. 2005 Transplant. Proc. pmid:15919452
Santiago SF et al. Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. 1992 Transplant. Proc. pmid:1376520
Tanaka M et al. Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. 1995 Transplant. Proc. pmid:7533392
Mitsuoka N et al. Cytokinic character of graft infiltrate versus peripheral blood lymphocytes during calcineurin inhibitor-resistant small bowel transplantation in rats. 2003 Transplant. Proc. pmid:12591532
Charco R et al. CD28 regulation in liver transplant recipients treated with two different immunosuppressive regimens. 1999 Transplant. Proc. pmid:10616508
Izuishi K et al. Effect of an immunosuppressive agent, tacroliums (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems of rat liver microsomes. 2003 Transplant. Proc. pmid:12591538
Kindt MV et al. Tacrolimus toxicity in rhesus monkey: model for clinical side effects. 1999 Transplant. Proc. pmid:10616519
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
Serrano J et al. Tacrolimus is effective in both dual and triple regimens after liver transplantation. 2002 Transplant. Proc. pmid:12176469
Troisi R et al. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? 2002 Transplant. Proc. pmid:12176470
du Toit DF et al. Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection. 1998 Transplant. Proc. pmid:9865300
Daoud AJ et al. A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus. 1998 Transplant. Proc. pmid:9865303
Cardinal H et al. The evolution of kidney function after lung transplantation: a retrospective cohort study. 2009 Transplant. Proc. pmid:19857746
Sarvary E et al. De novo Prograf versus de novo Advagraf: are trough level profile curves similar? Transplant. Proc. pmid:25131131
Hansen LJ et al. Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. 1997 Transplant. Proc. pmid:9142303
Oğütmen B et al. Transforming growth factor-beta1, vascular endothelial growth factor, and bone morphogenic protein-7 expression in tacrolimus-induced nephrotoxicity in rats. 2006 Transplant. Proc. pmid:16549155
Branco KC et al. The impact of tacrolimus as rescue therapy in children using a double immunosuppressive regimen after heart transplantation. 2012 Transplant. Proc. pmid:23026625
Prates LC et al. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report. 2012 Transplant. Proc. pmid:23026634
Weis M et al. Impact of immunosuppression on coronary endothelial function after cardiac transplantation. 1998 Transplant. Proc. pmid:9595131
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Valente G et al. Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting. 2013 Transplant. Proc. pmid:23622676
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Nishimoto Y et al. Real-time monitoring for detecting rejection using strain gauge force transducers in porcine small bowel transplantation. 2004 Transplant. Proc. pmid:15050153
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Urbizu JM et al. Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine. 2003 Transplant. Proc. pmid:12962765
Guy S et al. Successful treatment of acute severe graft-versus-host-disease in a pancreas-after-kidney transplant recipient: case report. 2014 Transplant. Proc. pmid:25179161
Montagnino G et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up. 2002 Transplant. Proc. pmid:12176515
Watanabe Y et al. Enteric absorption of FK 506: estimation by a block liver perfusion technique in rats. 1998 Transplant. Proc. pmid:9838656
Rayes N et al. Treatment of hepatitis B-reinfection or de novo-infection after liver transplantation with famciclovir--how effective is it? 1999 Feb-Mar Transplant. Proc. pmid:10083200
Shimizu T et al. Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. 2008 Transplant. Proc. pmid:18790237
Nanmoku K et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. 2008 Transplant. Proc. pmid:18790241
Nakajima H and Oka T Analysis of biochemical and biological functions of Fas-ligand (FasL) and Fas on activated T cells in allo-immune response. 1997 Feb-Mar Transplant. Proc. pmid:9123217
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Masaki Y et al. Cellular basis of immunologic tolerance following total bowel transplantation in rats. II. Dominant role of suppressor T cells in adoptive transfer of acquired tolerance to vascularized allografts. 1995 Transplant. Proc. pmid:7536972
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Iwamoto H et al. Early steroid withdrawal in adult kidney transplantation at a single center. 2012 Transplant. Proc. pmid:22310609
McGrath JS and Shehata M Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. 2001 Transplant. Proc. pmid:11377500
Baid S et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. 2002 Transplant. Proc. pmid:12176569
Kelly JS and Sharkey J Immunosuppressants-ligands as neuroprotectants. 2001 Transplant. Proc. pmid:11377506
Akioka K et al. Diabetes in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:12176570
Nakao A et al. Changes of allo-intestinal graft survival and intragraft cytokine expression by bone marrow augmentation with tacrolimus treatment in rats. 2001 Feb-Mar Transplant. Proc. pmid:11266851
Janezic AL et al. Alternatively spliced variants of IL-2 mRNA in sequential transplant kidney core needle biopsies. 2001 Feb-Mar Transplant. Proc. pmid:11266873
Chiba K et al. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. 1999 Feb-Mar Transplant. Proc. pmid:10083549
Armenti VT et al. Pregnancy outcomes in female renal transplant recipients. 1998 Transplant. Proc. pmid:9723259
Ju MK et al. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay? 2008 Transplant. Proc. pmid:19100463
Ash MM and Jolly PS A Case Report of the Resolution of Multiple Recalcitrant Verrucae in a Renal Transplant Recipient After a Mycophenolate Mofetil Dose Reduction. Transplant. Proc. pmid:28104140
Zucker MJ et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. 2005 Transplant. Proc. pmid:15964386
Kiberd BA et al. Impact of mycophenolate mofetil loading on drug exposure in the early posttransplant period. 2005 Transplant. Proc. pmid:15964408
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Goto T et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445072
Jain A et al. Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. 2002 Transplant. Proc. pmid:12176649
Veroux M et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. 2006 Transplant. Proc. pmid:16757256
Busque S et al. Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267285
Sperschneider H A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267291
Chu Z et al. Influence of immunosuppressive drugs on the development of CD4(+)CD25(high) Foxp3(+) T cells in liver transplant recipients. 2010 Transplant. Proc. pmid:20832552
Shapiro R Tacrolimus in solid organ transplantation: an update. 1999 Transplant. Proc. pmid:10500545
Martins L et al. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression. 2000 Transplant. Proc. pmid:11134735
Pirsch JD Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. 1998 Transplant. Proc. pmid:9723448
Antoine C et al. Vascular microthrombosis in renal transplant recipients treated with tacrolimus. 1998 Transplant. Proc. pmid:9745577
Fritsche L et al. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. 1998 Transplant. Proc. pmid:9723451
Fornairon S et al. Can we improve the results of simultaneous pancreas-kidney transplantation? 1998 Transplant. Proc. pmid:9745580
Hanack U et al. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? 1998 Transplant. Proc. pmid:9723477
Morales J et al. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. 2008 Transplant. Proc. pmid:19010240
Reiner J et al. After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. 2016 Transplant. Proc. pmid:27109987
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Itagaki F et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. 2002 Transplant. Proc. pmid:12431607
Spada M et al. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. 2001 Feb-Mar Transplant. Proc. pmid:11267495
Kuroki H et al. Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1703697